uploads/2018/07/Bridion.png

How Merck’s Bridion and Noxafil Performed in First Half of 2018

By

Updated

Bridion revenue trends

In the second quarter of 2018, Merck’s (MRK) Bridion generated revenues of $240.0 million compared to $163.0 million in the second quarter of 2017, reflecting ~47% year-over-year (or YoY) growth and ~18% growth sequentially. In the second quarter of 2018, in the US and international markets (outside the US markets), Bridion generated revenues of $95.0 million and $145.0 million, respectively, compared to $54.0 million and $109.0 million during the same period last year, reflecting ~78% and ~33% YoY growth.

Article continues below advertisement

In the first half of 2018, Bridion generated revenues of $444.0 million, reflecting ~43% YoY growth. In the first half of 2018, Bridion generated revenues of $175.0 million and $269.0 million from sales in the US and international markets, respectively, which is ~77% and ~27% YoY growth. Bridion is used for the reversal of neuromuscular blockade in patients who underwent surgery using rocuronium bromide and vecuronium bromide.

Noxafil revenue trends

Noxafil generated revenues of $188.0 million in the second quarter of 2018, reflecting ~21% YoY growth and 7% sequential growth. In the second quarter of 2018, in US and international markets, Noxafil generated revenues of $87.0 million and $100.0 million, respectively, reflecting ~13% and ~29% YoY growth.

In the first half of 2018, Noxafil generated revenues of $363.0 million compared to $296.0 million in the first half of 2017, reflecting ~23% YoY growth. In the first half of 2018, in the US and international markets, Noxafil reported revenues of $168.0 million and $195.0 million, respectively, reflecting ~19% and ~26% YoY growth.

Noxafil is used for the prevention of invasive Aspergillus and Candida infection in individuals who are immuno-compromised such as individuals who underwent HSCT (hematopoietic stem cell transplant), individuals with graft-versus-host-disease, and patients undergoing chemotherapy due to hematologic malignancies.

Notably, Pfizer’s (PFE) Vfend, Noxafil’s peer, generated revenues of $110.0 million and $207.0 million in the first half and second quarter of 2018, respectively.

Advertisement

More From Market Realist